The conservation of BRAF and MAP2K1 deletions in canine UC and human LCH and pancreatic carcinomas suggests there may be synergistic benefit from parallel functional studies of these diverse cancer types, as a means to better understand the broader relationship between somatic alteration, protein conformation and therapeutic sensitivity. The gene discussed is BRAF; the disease is exocrine pancreatic carcinoma.